Teva Oncology offers the Comprehensive Oncology Reimbursement Expertise (CORE) program and the Teva Cares Foundation Patient Assistance Program to help patients while taking a Teva Oncology treatment (Table).
The Teva CORE program helps eligible patients, their caregivers, and healthcare professionals navigate the reimbursement process through a range of services, including benefit verification, coverage determination, prior authorizations, letters of medical necessity, and referrals to the Teva Cares Foundation.
For patients prescribed Granix, Herzuma, and Truxima, Teva CORE offers a Patient Savings Program. Patients may be eligible for this if they:
Are at least 18 years of age
Have commercial insurance
Do not participate in Medicare, Medicaid, or other government insurance program.
Click here to enroll your patient in the Teva CORE program.
Teva Cares Foundation Patient Assistance Program
If your patient is uninsured or underinsured, they may be eligible to receive their prescribed Teva medication at no cost. Patients must meet certain financial and insurance coverage criteria to be eligible. Patient Assistance Program applications are available online.
Treatment of HER2-overexpressing node-positive or -negative breast cancer, in combination with doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel, or in combination with docetaxel and carboplatin; as monotherapy after anthracycline-based therapy; first-line treatment of HER2-overexpressing metastatic breast cancer, in combination with paclitaxel, or as monotherapy in patients who received ≥1 chemotherapy regimens for metastatic disease; treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, in combination with cisplatin and capecitabine or 5-fluorouracil, in patients who have not received previous therapy for metastatic disease
Truxima (rituximab-abbs) Indications
Treatment of adults with relapsed or refractory, low-grade or follicular, CD20-positive B-cell NHL as a single agent; treatment of previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; treatment of non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy; treatment of previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or other anthracycline-based chemotherapy regimens; treatment of previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide